Page 228 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 12 Cancer Chemotherapy 207

343. Kisseberth WC, Vail DM, Yaissle J, et al.: Phase I clinical evalua- 363. Hahn KA, Ogilvie G, Rusk T, et al.: Masitinib is safe and effec-
tion of carboplatin in tumor-bearing cats: a veterinary cooperative tive for the treatment of canine mast cell tumors, J Vet Intern Med
oncology group study, J Vet Intern Med 22:83–88, 2008. 22:1301–1309, 2008.
VetBooks.ir 344. Bailey DB, Rassnick KM, Prey JD, et al.: Evaluation of serum 364. Merrick CH, Pierro J, Schleis SE, et al.: Retrospective evaluation
®
of toceranib phosphate (Palladia ) toxicity in cats, Vet Comp Oncol
iohexol clearance for use in predicting carboplatin clearance in cats,
15:710–717, 2017.
Am J Vet Res 70:1135–1140, 2009.
345. Bailey DB, Rassnick KM, Dykes NL, et al.: Phase I evaluation of 365. Harper A, Blackwood L: Toxicity and response in cats with neo-
carboplatin by use of a dosing strategy based on a targeted area plasia treated with toceranib phosphate, J Feline Med Surg 19:619–
under the platinum concentration-versus-time curve and indi- 623, 2017.
vidual glomerular filtration rate in cats with tumors, Am J Vet Res 366. Daly M, Sheppard S, Cohen N, et al.: Safety of masitinib mesylate
70:770–776, 2009. in healthy cats, J Vet Intern Med 25:297–302, 2011.
346. Arteaga TA, McKnight J, Bergman PJ: A review of 18 cases of feline 367. Tjostheim SS, Stepien RL, Markovic LE, et al.: Effects of toceranib
colonic adenocarcinoma treated with subtotal colectomies and phosphate on systolic blood pressure and proteinuria in dogs, J Vet
adjuvant carboplatin, J Am Anim Hosp Assoc 48:399–404, 2012. Intern Med 30:951–957, 2016.
347. Morgan JS, Creasey DC, Wright JA: Evidence that the antitumor 368. London C, Mathie T, Stingle N, et al.: Preliminary evidence for
®
agent hydroxyurea enters mammalian cells by a diffusion mecha- biologic activity of toceranib phosphate (Palladia ) in solid tumours,
nism, Biochem Biophys Res Commun 134:1254–1259, 1986. Vet Comp Oncol 10:194–205, 2012.
348. Turner MK, Abrams R, Lieberman I: Meso-alpha, beta- 369. Weishaar KM, Ehrhart EJ, Avery AC, et al.: C-kit mutation and
diphenylsuccinate and hydroxyurea as inhibitors of deoxycyti- localization status as response predictors in mast cell tumors in dogs
dylate synthesis in extracts of ehrlich ascites and l cells, J Biol Chem treated with prednisone and toceranib or vinblastine, J Vet Intern
241:5777–5780, 1966. Med 32:394–405, 2018.
349. Skoog L, Nordenskjold B: Effects of hydroxyurea and 1-beta-d- 370. Elliott JW, Swinbourne F, Parry A, et al.: Successful treatment of a
arabinofuranosyl-cytosine on deoxyribonucleotide pools in mouse metastatic, gastrointestinal stromal tumour in a dog with toceranib
embryo cells, Eur J Biochem 19:81–89, 1971. phosphate (Palladia), J Small Anim Pract 58:416–418, 2017.
350. veer Reddy GP, Pardee AB: Inhibitor evidence for allosteric inter- 371. London CA, Gardner HL, Mathie T, et al.: Impact of toceranib/
action in the replitase multienzyme complex, Nature 304:86–88, piroxicam/cyclophosphamide maintenance therapy on outcome of
1983. dogs with appendicular osteosarcoma following amputation and
351. Bianchi V, Pontis E, Reichard P: Changes of deoxyribonucleoside carboplatin chemotherapy: a multi-institutional study, PLoS One
triphosphate pools induced by hydroxyurea and their relation to 10:e0124889, 2015.
DNA synthesis, J Biol Chem 261:16037–16042, 1986. 372. Kim C, Matsuyama A, Mutsaers AJ, et al.: Retrospective evaluation
352. Rassnick KM, Al-Sarraf R, Bailey DB, et al.: Phase II open-label of toceranib (Palladia) treatment for canine metastatic appendicular
study of single-agent hydroxyurea for treatment of mast cell osteosarcoma, Can Vet J 58:1059–1064, 2017.
tumours in dogs, Vet Comp Oncol 8:103–111, 2010. 373. Isotani M, Ishida N, Tominaga M, et al.: Effect of tyrosine kinase
353. Story MD, Voehringer DW, Stephens LC, et al.: l-Asparaginase inhibition by imatinib mesylate on mast cell tumors in dogs, J Vet
kills lymphoma cells by apoptosis, Cancer Chemother Pharmacol Intern Med 22:985–988, 2008.
32:129–133, 1993. 374. Lachowicz JL, Post GS, Brodsky E: A phase I clinical trial evaluat-
354. Chabner BA, Sallan SE: Enzyme therapy: l-asparaginase. In Chab- ing imatinib mesylate (Gleevec) in tumor-bearing cats, J Vet Intern
ner BA, Longo DL, editors: Cancer chemotherapy & biotherapy: Med 19:860–864, 2005.
principles and practice, ed 3, Philadelphia, 2001, Lippincott WIl- 375. Su AI, Welsh JB, Sapinoso LM, et al.: Molecular classification of
liams & Wilkins, pp 647–656. human carcinomas by use of gene expression signatures, Cancer Res
355. London CA, Hannah AL, Zadovoskaya R, et al.: Phase I dose-esca- 61:7388–7393, 2001.
lating study of SU11654, a small molecule receptor tyrosine kinase 376. Golub TR, Slonim DK, Tamayo P, et al.: Molecular classification
inhibitor, in dogs with spontaneous malignancies, Clin Cancer Res of cancer: class discovery and class prediction by gene expression
9:2755–2768, 2003. monitoring, Science 286:531–537, 1999.
356. London CA: Tyrosine kinase inhibitors in veterinary medicine, Top 377. Moseson DL, Sasaki GH, Kraybill WG, et al.: The use of anties-
Companion Anim Med 24:106–112, 2009. trogens tamoxifen and nafoxidine in the treatment of human breast
357. London CA, Malpas PB, Wood-Follis SL, et al.: Multi-center, placebo- cancer in correlation with estrogen receptor values: a phase II study,
controlled, double-blind, randomized study of oral toceranib phosphate Cancer 41:797–802, 1978.
(SU11654), a receptor tyrosine kinase inhibitor, for the treatment of 378. Flaherty KT, Puzanov I, Kim KB, et al.: Inhibition of mutated,
dogs with recurrent (either local or distant) mast cell tumor following activated BRAF in metastatic melanoma, N Engl J Med 363:809–
surgical excision, Clin Cancer Res 15:3856–3865, 2009. 819, 2010.
358. Papaetis GS, Syrigos KN: Sunitinib: a multitargeted receptor tyro- 379. Paez JG, Janne PA, Lee JC, et al.: Egfr mutations in lung can-
sine kinase inhibitor in the era of molecular cancer therapies, Bio- cer: correlation with clinical response to gefitinib therapy, Science
Drugs 23:377–389, 2009. 304:1497–1500, 2004.
359. Dubreuil P, Letard S, Ciufolini M, et al.: Masitinib (AB1010), a 380. Ueda K, Cornwell MM, Gottesman MM, et al.: The mdr1 gene,
potent and selective tyrosine kinase inhibitor targeting kit, PLoS responsible for multidrug-resistance, codes for p-glycoprotein, Bio-
One 4:e7258, 2009. chem Biophys Res Commun 141:956–962, 1986.
360. Fabian MA, Biggs WH, Treiber DK, et al.: A small molecule- 381. Mauldin G, Matus R, Patnaik A, et al.: Efficacy and toxicity of
kinase interaction map for clinical kinase inhibitors, Nat Biotechnol doxorubicin and cyclophosphamide used in the treatment of
23:329–336, 2005. selected malignant tumors in 23 cats, J Vet Intern Med 2:60–65,
361. Yancey MF, Merritt DA, Lesman SP, et al.: Pharmacokinetic prop- 1988.
erties of toceranib phosphate (Palladia, SU11654), a novel tyrosine 382. Herzog TJ, Krivak TC, Fader AN, et al.: Chemosensitivity testing
kinase inhibitor, in laboratory dogs and dogs with mast cell tumors, with chemofx and overall survival in primary ovarian cancer, Am J
J Vet Pharmacol Ther 33:162–171, 2010. Obstet Gynecol 203:68 e61–66, 2010.
362. Yancey MF, Merritt DA, White JA, et al.: Distribution, metabo- 383. Wakatsuki T, Irisawa A, Imamura H, et al.: Complete response of
lism, and excretion of toceranib phosphate (Palladia, SU11654), anaplastic pancreatic carcinoma to paclitaxel treatment selected by
a novel tyrosine kinase inhibitor, in dogs, J Vet Pharmacol Ther chemosensitivity testing, Int J Clin Oncol 15:310–313, 2010.
33:154–161, 2010.